Navigation Links
Arena Pharmaceuticals to Present at the 34th Annual Deutsche Bank Health Care Conference
Date:5/13/2009

SAN DIEGO, May 13, 2009 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today that the company is scheduled to present at the 34th Annual Deutsche Bank Health Care Conference on May 19, 2009 at 10:10 a.m. Eastern Time (7:10 a.m. Pacific Time) at the InterContinental Boston Hotel in Boston. Dominic P. Behan, Ph.D., Arena's Senior Vice President and Chief Scientific Officer, is scheduled to provide an overview of the company, including its clinical development and research programs.

A live audio webcast of the presentation will be available under the investor relations section of Arena's website at www.arenapharm.com. A replay of the presentation will be available for 30 days following the event. Please connect to Arena's website several minutes prior to the start of the webcast to ensure adequate time for any software download that may be necessary.

About Arena Pharmaceuticals

Arena is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing oral drugs in four major therapeutic areas: cardiovascular, central nervous system, inflammatory and metabolic diseases. Arena's most advanced drug candidate, lorcaserin, is being investigated in a Phase 3 clinical trial program for weight management. Arena's broad pipeline of novel compounds target G protein-coupled receptors, an important class of validated drug targets, and includes compounds being evaluated independently and with partners, including Merck & Co., Inc., and Ortho-McNeil-Janssen Pharmaceuticals, Inc.

Arena Pharmaceuticals(R) and Arena(R) are registered service marks of the company. "APD" is an abbreviation for Arena Pharmaceuticals Development.

Forward-Looking Statements

Certain statements in this press release are forward-looking statements that involve a number of risks and uncertainties. Such forward-looking statements include statements about Arena's strategy, internal and partnered programs, and ability to develop compounds and commercialize drugs. For such statements, Arena claims the protection of the Private Securities Litigation Reform Act of 1995. Actual events or results may differ materially from Arena's expectations. Factors that could cause actual results to differ materially from the forward-looking statements include, but are not limited to, Arena's ability to obtain additional funds; the timing, success and cost of Arena's lorcaserin program and other of its research and development programs; results of clinical trials or preclinical studies may not be predictive of future results; clinical trials and studies may not proceed at the time or in the manner Arena expects or at all; Arena's ability to partner lorcaserin or other of its compounds or programs; the timing and ability of Arena to receive regulatory approval for its drug candidates; Arena's ability to obtain and defend its patents; and the timing and receipt of payments and fees, if any, from Arena's collaborators. Additional factors that could cause actual results to differ materially from those stated or implied by Arena's forward-looking statements are disclosed in Arena's filings with the Securities and Exchange Commission. These forward-looking statements represent Arena's judgment as of the time of this release. Arena disclaims any intent or obligation to update these forward-looking statements, other than as may be required under applicable law.

    Contacts:  Jack Lief
               President and Chief Executive Officer

               Cindy McGee
               Senior Communications Associate

               Arena Pharmaceuticals, Inc.
               858.453.7200, ext. 1479

               Mary Claire Duch
               WeissComm Partners
               Media Relations
               212.301.7228


'/>"/>
SOURCE Arena Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Arena Pharmaceuticals Announces Positive Lorcaserin Pivotal Phase 3 Obesity Trial Results: Meets All Primary Efficacy and Safety Endpoints
2. Arena Pharmaceuticals to Report Fourth Quarter and Full Year 2008 Financial Results and to Host Conference Call and Webcast on Thursday, March 12, 2009
3. Arena Pharmaceuticals Announces Initiation by Merck of Phase 2 Clinical Trial of Niacin Receptor Agonist
4. Arena Pharmaceuticals to Present at the BIO CEO & Investor Conference
5. Arena Pharmaceuticals to Host Research & Development Day on December 15, 2008
6. Arena Pharmaceuticals Announces Lorcaserin Phase 2b Clinical Trial Results Published in Obesity
7. Arena Pharmaceuticals to Present at the Piper Jaffray 20th Annual Health Care Conference
8. Arena Pharmaceuticals Announces Third Quarter 2008 Financial Results
9. Childrens Miracle Network and Arena Football League Partner for First Nationwide Celebration Event
10. Field Poll: California Nurses Association Most Favorably Viewed Group in Healthcare Arena
11. Arena Pharmaceuticals to Report First Quarter 2008 Financial Results and to Host Conference Call and Webcast on Wednesday, May 7, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2016)... ... May 25, 2016 , ... Laser Skin & Wellness Center ... hands of time of female aging. The Juliet™ procedure helps to ... such as leakage, laxity, itchiness and pain have reported real relief from these and ...
(Date:5/25/2016)... NJ (PRWEB) , ... May 25, 2016 , ... Researchers ... 2016 Annual COVD Meeting for their work on visual evoked potential and human attention. ... recent studies that used the Diopsys® NOVA™ ERG and VEP Vision Testing System ...
(Date:5/25/2016)... (PRWEB) , ... May 25, 2016 , ... ... builder, has announced that it will join America's leading engineers at the American ... held at the Georgia World Congress Center. , Engineers, speakers and exhibitors ...
(Date:5/24/2016)... ... May 24, 2016 , ... According to an article published ... randomly assigned to reduce the amount of calories they consumed by 25% experienced some ... weight enjoyed better sleep, improved quality of life, and enhanced sexual function compared to ...
(Date:5/24/2016)... ... 2016 , ... PhishLine, the best-in-class, enterprise level security solutions ... President of Sales. Cifolelli’s primary responsibilities include management of the company’s sales ... field of organizational social engineering. , “We are delighted to have Rudy ...
Breaking Medicine News(10 mins):
(Date:5/24/2016)... LONDON , May 24, 2016 ... erfüllt beide primären Endpunkte ... und Überlegenheit in ‚ausgezeichneter plus guter ... aufsteigenden Colons    ,      (Logo: ... B.V. gab heute neue positive Daten von der ...
(Date:5/24/2016)... May 24, 2016 ARANZ Medical ... the healthcare sector, has been named the Coretex Hi-Tech Emerging ... 2016. Dr Bruce Davey , CEO of ... team.  It,s really good to be recognised for the work ... products are used in 35 countries around the world from ...
(Date:5/24/2016)... 2016  Joe Marziani has joined VMS BioMarketing as senior vice president of sales, ... his new role, Marziani will lead the company,s business development and sales team, exploring ... Photo - http://photos.prnewswire.com/prnh/20160523/371089 ... ... ...
Breaking Medicine Technology: